Yes. The FDA has issued warning letters, seized products, and obtained injunctions against sellers marketing unapproved peptides with therapeutic claims. They've also sent cease-and-desist letters to compounding pharmacies producing semaglutide and tirzepatide. The FDA's enforcement tends to focus on domestic sellers making explicit health claims rather than overseas research chemical suppliers. This enforcement activity is one driver of supply shifts in the gray market.